Brief: Dermapharm Holding Sees Adjusted Consolidated EBITDA Between EUR 300 And 310 Mln In 2023

Dermapharm Holding SE

28/03/2023 06:34

March 28 (Reuters) - DERMAPHARM HOLDING SE  DMPG.DE :
    * SURPASSES ONE BILLION IN REVENUE FOR FIRST TIME IN 2022
AND
MAINTAINS GROWTH TRAJECTORY
    * DIVIDEND PROPOSAL OF EUR 1.05 PER SHARE FOR 2022
    * ADJUSTED CONSOLIDATED EBITDA EXPECTED TO AMOUNT TO BETWEEN
EUR
300 AND 310 MILLION IN 2023
    * CONSOLIDATED REVENUE EXPECTED TO INCREASE TO BETWEEN EUR
1,080
AND 1,110 BILLION IN 2023
    * FY CONSOLIDATED REVENUE RISES 8.7% TO EUR 1,024.8 MILLION
    * FY ADJUSTED CONSOLIDATED EBITDA GROWS BY 2.5% TO EUR 359.8
MILLION

Source text for Eikon:  ID:nEQbDV6hta 
Further company coverage:  DMPG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))